Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease

Pharmacoeconomics. 2009;27(7):609-21

View abstract

Authors

Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM